VRNO:CNSX-Verano Holdings Corp (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | CNSX

Last Closing Price

CAD 6.97

Change

0.00 (0.00)%

Market Cap

CAD 2.99B

Volume

0.11M

Avg Analyst Target

CAD 13.50 (+93.69%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


VRNO Stock Forecast & Price:
Based on the Verano Holdings Corp stock forecasts from 3 analysts, the average analyst target price for Verano Holdings Corp is CAD 13.50 over the next 12 months. Verano Holdings Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Verano Holdings Corp is Slightly Bullish , which is based on 2 positive signals and 1 negative signals. At the last closing, Verano Holdings Corp’s stock price was CAD 6.97. Verano Holdings Corp’s stock price has changed by +2.50% over the past week, -18.00% over the past month and -56.57% over the last year.

About Verano Holdings Corp (VRNO:CA:CNSX)

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CURA:CA Curaleaf Holdings Inc

N/A

CAD5.50B N/A 21.13
GTII:CA Green Thumb Industries Inc

N/A

CAD3.35B 25.78 9.77
TRUL:CA Trulieve Cannabis Corp

N/A

CAD3.23B 121.35 16.72
HARV:CA Harvest Health & Recreation In..

N/A

CAD1.65B N/A 122.88
CL:CA Cresco Labs Inc

N/A

CAD1.30B N/A -12.23
CCHW:CA Columbia Care Inc

N/A

CAD0.86B N/A -26.36
PLTH:CA Planet 13 Holdings Inc

N/A

CAD0.53B N/A 246.11
JUSH:CA Jushi Holdings Inc

N/A

CAD0.52B N/A 6.63
LHS:CA Liberty Health Sciences Inc

N/A

CAD0.51B 147.00 13.82
IAN:CA iAnthus Capital Holdings Inc

N/A

CAD0.47B N/A 51.94

ETFs Containing VRNO:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -56.41% 46% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.41% 46% F 37% F
Trailing 12 Months  
Capital Gain -56.57% 74% C 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.57% 74% C 55% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.23% 67% D+ 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.23% 67% D+ 45% F
Risk Return Profile  
Volatility (Standard Deviation) 23.87% 89% B+ 84% B
Risk Adjusted Return -51.24% 59% F 42% F
Market Capitalization 2.99B 98% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.46 38% F 30% F
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.